Noopept

Russian dipeptide nootropic developed at the Zakusov Institute (Ostrovskaya lab, late-1990s, registered 2002) — orally-active prodrug for cycloprolylglycine (cPG), an endogenous human CNS dipeptide. Subjectively rapid clarity + verbal fluency + mild anxiolytic with low side-effect ceiling; mechanism is BDNF/NGF upregulation + AMPA potentiation + cholinergic restoration. The "~1000× more potent than piracetam" claim is mass-basis, not effect magnitude. For Dylan: WATCH-LIST — credible compound but redundant with his already-strong Russian-peptide stack (Semax + Bromantane + Adamax). Promote to OPTIONAL-ADD only if a stack slot opens or a sublingual fast-onset option is wanted.

Noopept is fundamentally a dipeptide prodrug. The parent molecule, N-phenylacetyl-L-prolylglycine ethyl ester (GVS-111), is engineered for oral bioavailability and BBB penetration. Once across the BBB, it is rapidly hydrolyzed by prolyl-endopeptidase to release the active metabolite — cycloprolylglycine (cPG), which is itself an endogenous human CNS dipeptide. This is the most pharmacologically interesting feature of noopept: rather than being a foreign small molecule, the active form is a dipeptide already present in human brain tissue, making noopept structurally a substrate-augmenter for an endogenous peptide system.

1. cPG upregulation → BDNF + NGF transcriptional increase (the dominant claimed mechanism). Ostrovskaya and colleagues demonstrated that chronic noopept administration increases BDNF and NGF mRNA + protein in rat hippocampus and cortex, with effect sizes approaching ~1.5–2× baseline at therapeutic doses. The proposed signaling chain is: noopept → cPG → CREB-dependent transcription of neurotrophin genes → TrkB/TrkA receptor activation → MAPK/ERK + PI3K/Akt cascades → enhanced synaptic plasticity, neuronal survival, dendritic complexity. This is the mechanistic basis for Russian framing of noopept as both a nootropic (cognitive enhancement) and neuroprotective (post-ischemic, post-toxic) agent.

2. AMPA receptor potentiation (secondary). Noopept appears to function as a positive allosteric modulator of AMPA receptors — the glutamate-side complement to its trophic action. Effect size is modest compared to dedicated AMPA PAMs (TAK-653, ACD-856, racetams like aniracetam), but contributes to the rapid onset of subjective cognitive effects (within 15–30 minutes sublingual, before BDNF transcription could plausibly take effect). The acute clarity reported by users is mechanistically more consistent with AMPA modulation than with neurotrophin upregulation.

3. Cholinergic restoration. In cholinergic-deficit models (scopolamine challenge, AF64A lesion, aged rats), noopept partially restores acetylcholine tone, hippocampal nicotinic responsiveness, and learning performance. Mechanism is not direct cholinergic agonism — it appears to be downstream of the trophic effect on cholinergic neurons + possible enhancement of hippocampal cholinergic sprouting. This restoration profile is why noopept testing has heavily favored Alzheimer's-relevant and post-stroke cognitive impairment models.

4. Anxiolytic + mild antidepressant. Russian preclinical and clinical literature reports anxiolytic action distinct from benzodiazepine pharmacology — no GABA-A binding, no sedation. Mechanism likely combines (a) cPG's documented endogenous anxiolytic role, (b) BDNF-mediated stress resilience, (c) modest 5-HT and DA modulation in stress-state animal models. Magnitude is mild; not a substitute for dedicated anxiolytics like Selank.

5. Antioxidant + membrane-protective. Reduces lipid peroxidation, normalizes glutathione system markers, decreases reactive oxygen species in ischemic and toxic neuronal models. Mechanism is partly direct (radical scavenging) and partly indirect (BDNF-mediated upregulation of antioxidant enzyme expression). This is the framing for Russian use in post-stroke rehabilitation and cerebrovascular insufficiency.

6. Anti-amyloid signal (preclinical). Several Ostrovskaya papers describe reduced amyloid-β toxicity in vitro and in transgenic AD mouse models — mechanism interpreted as a combination of trophic protection + reduced amyloid aggregation. Not yet replicated in independent labs at the level required for translational claims.

Pharmacokinetics:

• Oral bioavailability: Moderate — parent molecule is well-absorbed but extensively hydrolyzed first-pass; functional CNS exposure is via the cPG metabolite, not the parent.
• Tmax (oral): 60–90 minutes for parent molecule plasma; functional cognitive onset reported at 15–60 minutes (suggesting partial activity from parent + rapid CNS hydrolysis to cPG).
• Tmax (sublingual): 15–30 minutes for subjective effect onset; bypasses some first-pass hepatic metabolism, may yield slightly higher CNS exposure of parent before hydrolysis.
• Plasma half-life of parent: ~30–50 minutes (extensively cleared by hydrolysis).
• CNS effect duration: 4–8 hours per dose subjectively; downstream BDNF transcription effects persist 12–24 hours, full neurotrophic signature compounds across days/weeks.
• Elimination: Primarily as inactive cPG-derivative metabolites in urine.
• Active metabolite endogeneity: cPG circulates in healthy human CSF at low picomolar concentrations baseline; noopept administration measurably elevates this — meaning noopept is, mechanistically, a way to push an existing endogenous signaling system rather than introducing a foreign one.